BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16893590)

  • 1. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
    Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H
    Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up.
    Destro A; Ceresoli GL; Baryshnikova E; Garassino I; Zucali PA; De Vincenzo F; Bianchi P; Morenghi E; Testori A; Alloisio M; Santoro A; Roncalli M
    Lung Cancer; 2008 Mar; 59(3):369-76. PubMed ID: 17920725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
    De Schutter H; Geeraerts H; Verbeken E; Nuyts S
    Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
    Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
    Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
    Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
    Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
    Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
    Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M
    Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
    Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
    Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients.
    Yuregir OO; Yurtcu E; Kizilkilic E; Kocer NE; Ozdogu H; Sahin FI
    Int J Lab Hematol; 2010 Apr; 32(2):142-9. PubMed ID: 19302404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma.
    Li J; El-Naggar A; Mao L
    Cancer; 2005 Aug; 104(4):771-6. PubMed ID: 15959912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
    Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma.
    Kwong J; Lo KW; To KF; Teo PM; Johnson PJ; Huang DP
    Clin Cancer Res; 2002 Jan; 8(1):131-7. PubMed ID: 11801549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.
    Chan MW; Chan LW; Tang NL; Tong JH; Lo KW; Lee TL; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
    Clin Cancer Res; 2002 Feb; 8(2):464-70. PubMed ID: 11839665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
    Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
    Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
    J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion.
    Katayama H; Hiraki A; Aoe K; Fujiwara K; Matsuo K; Maeda T; Murakami T; Toyooka S; Sugi K; Ueoka H; Tanimoto M
    Int J Cancer; 2007 May; 120(10):2191-5. PubMed ID: 17285579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer.
    Sugita H; Iida S; Inokuchi M; Kato K; Ishiguro M; Ishikawa T; Takagi Y; Enjoji M; Yamada H; Uetake H; Kojima K; Sugihara K
    Oncol Rep; 2011 Feb; 25(2):513-8. PubMed ID: 21152877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.